Gene transfer to the dorsal root ganglion using replication defective herpes simplex virus (HSV)-based vectors reduces pain-related behaviors in rodent models having inflammatory pain, neuropathic pain and pain caused by cancer in bone. HSV vectors engineered to produce inhibitory neurotransmitters, including the delta opioid agonist peptide enkephalin, the mu opioid agonist peptide endomorphin-2 and glutamic acid decarboxylase (GAD), to effect the release of gamma amino butyric acid (GABA) act to inhibit nociceptive neurotransmission at the first synapse between primary nociceptive and second-order neuron in the dorsal horn of the spinal cord.
The development of novel effective treatments for chronic pain has been disappointingly slow. In part, this is because the conservative use of a limited repertoire of neurotransmitters, receptors and ion channels at multiple sites and in many converging and diverging pathways serving different functions in the nervous system that limits the ability to use systemically administered small molecules to selectively interrupt nociceptive neurotransmission. 1 To overcome this limitation we have constructed a series of non-replicating herpes simplex virus (HSV)-based vectors that efficiently target gene delivery to dorsal root ganglia (DRG) neurons from skin inoculation 2, 3 to effect the release of antinociceptive neurotransmitters from afferent DRG terminals in a regionally restricted manner in the dorsal horn of spinal cord.
The neuroanatomic pathways involved in the complex process of pain perception are well established. Primary nociceptors are pseudounipolar neurons with cell bodies in the dorsal root ganglion and axons that terminate peripherally in the skin or organs and project centrally to terminate in the dorsal horn of spinal cord in an anatomically defined (dermatomal or radicular) pattern. Second-order neurons project from the spinal cord principally to sensory nuclei in the thalamus. Thirdorder neurons in the thalamus project to sensory cortex to subserve the discriminative aspects of pain perception, and to limbic cortex to subserve the hedonic aspects of the pain experience. Many disparate regions of brain are subsequently recruited. In addition to the ascending pathways, descending pathways that ultimately project from the brainstem back to the spinal-dorsal horn act to modulate primary nociceptive neurotransmission at the first synapse in the dorsal horn.
Gene transfer methods may be used to achieve continuous focal expression of short-lived analgesic peptides at several sites in the ascending pain pathway, with the aim of selectively interrupting nociceptive neurotransmission although limiting the occurrence of off-target effects. In rodent models, alteration in nociception has been achieved by gene transfer into brain nuclei (rostral agranular insular cortex, 4 amygdala 5 ), transduction of the meninges to result in release into cerebrospinal fluid [6] [7] [8] direct injection of vector into the dorsal horn of spinal cord, 9 and transduction of DRG either by injection of vector directly into DRG 10 or into the intrathecal space.
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The first synapse between the primary nociceptor and the second-order projection neuron in the spinal cord is particularly an attractive target because of the ability to block nociception selectively at that level, thereby preventing the perception of pain. 12 This site has been exploited using conventional analgesic drugs (for example, morphine, baclofen) by delivery through chronic intrathecal infusion. Intrathecal administration results in a 10-fold reduction in dose requirement and a reduction in off-target adverse events. But even with this devicedirected approach, problems remain in effectiveness and tolerance.
The first HSV vector tested with analgesic properties was a replication competent vector that expressed preproenkephalin to effect the release of enkephalin peptides from transduced neurons. Pohl et al. 13 demonstrated that inoculation of the vector into the footpad results in strong expression of preproenkephalin mRNA in the dorsal root ganglion and a substantial increase in radioimmunoassay detected met enkephalin-like material in the DRG and in the dorsal horn of the spinal cord. Wilson et al. 14 demonstrated that subcutaneous inoculation of the vector interferes with the hyperalgesic response of Ad and C fibers sensitized with dimethylsulfoxide or capsaicin, respectively. This was followed by the demonstration that inoculation of the vector into the foot reduces pain-related behaviors in adjuvant-induced polyarthritis in the rat. 15 Our initial studies of the properties of a replication defective HSV vector expressing preproenkephalin demonstrated efficacy in the formalin test. 16 We found that inoculation of the vector subcutaneously into the plantar surface of the hind foot reduces pain-related behaviors in the delayed phase of the formalin test. The vector-mediated effect was maximal in animals inoculated with the vector 1 week before formalin test and diminished in magnitude over the course of the subsequent 3 weeks. 16 Two lines of indirect evidence support the interpretation that the reduction in analgesic effectiveness of the vector is not subject to the development of tolerance to vector-mediated enkephalin released from the nerve terminals. First, reinoculation of the enkephalin-expressing vector into the foot 4 weeks after the initial inoculation reestablished a substantial analgesic effect in animals tested 1 week after the reinoculation. Second, the time course of the effect produced by this vector, in which enkephalin expression is driven by the human cytomegalovirus immediate early promoter, is similar to the time course that we have observed in other experiments using the human cytomegalovirus immediate early promoter to drive expression of other transgenes from non-replicating HSV vectors in vivo. 17, 18 In the selective L5 spinal nerve ligation model of neuropathic pain, inoculation of the replication defective enkephalin-expressing HSV vector into the foot 1 week after spinal nerve ligation results in a statistically significant attenuation in mechanical allodynia that persisted for several weeks. 19 During that time, antiallodynic effect of the vector is continuous throughout the day. As in the formalin model, the effect of vectormediated enkephalin release persists for several weeks and is reestablished by reinoculation. Pharmacologically, the effect of vector-mediated enkephalin is additive with systemically administered morphine, reducing the ED 50 of morphine from 1.8 mg kg À1 in vehicle-or control-treated animals with spinal nerve ligation to 0.15 mg kg À1 in animals with spinal nerve ligation and inoculated with the enkephalin-expressing vector. We found that the vector-mediated enkephalin effect persists in animals rendered tolerant to morphine by repeated twice-daily administration of the drug. 19 Finally, in a model of cancer-related pain created by implantation of sarcoma cells into the medullary space of the femur, subcutaneous inoculation of the enkephalin-expressing HSV vector results in a significant naltrexone reversible decrease in pain-related behavior assessed by open field motor activity. 20 In order to target the spinal mu opioid receptor we constructed an HSV vector to express endomorphin-2, a carboxy-amidated tetrapeptide identified from bovine brain extracts as a highly selective mu opioid receptor ligand. 21 The engineered expression cassette consists of the 99 N-terminal amino-acid residues of the human preproenkephalin gene to direct the polypeptides into the secretory pathway for proteolytic processing, followed by a pair of endomorphin-2 coding elements each flanked by dibasic cleavage sites to provide for processing and peptide liberation by cellular proteases. Each endomomorphin-2 moiety contains a C-terminal glycine residue extension to direct processing by the ubiquitous peptidyl-glycine a-amidating monooxygenase to yield C-terminal amidation of the cleaved peptide. 22 Subcutaneous inoculation of the endomorphin-expressing HSV vector into the footpad results in a substantial reduction in nocisponsive behaviors in response to mechanical and thermal stimuli in the complete Freund's adjuvant model of inflammatory pain ( Figure 1 ) and reduced spontaneous pain behaviors in the delayed phase of the formalin test. 23 In the selective spinal nerve ligation model of neuropathic pain, subcutaneous inoculation of the endomorphin-expressing HSV vector reduces both mechanical allodynia and thermal hyperalgesia, 22 an effect that is similar in magnitude to the effect produced by the enkephalin expressing vector in the same model.
The anti-allodynic effects of the enkephalin-and endomorphin-expressing vectors in neuropathic pain, although statistically significant, are incomplete; an outcome that is not entirely unexpected given the limited effectiveness of opiate drugs in the treatment of neuropathic pain. Owing to substantial evidence suggesting a selective loss of GABA (gamma amino butyric acid)ergic inhibition in the dorsal horn of spinal cord in the setting of peripheral nerve injury we constructed an HSV vector to express glutamic acid decarboxylase, the enzyme that catalyzes the conversion of glutamate to GABA. 24 For this purpose we used glutamic acid decarboxylase 67 (GAD67), the 'glial' isoform of the enzyme that localizes in the cytoplasm and whose activity is relatively independent of regulatory controls. Infection of primary dorsal root ganglion neurons in culture with the GADexpressing HSV vector results in the production of GAD67 protein and the constitutive release of GABA from the cells through the GABA transporter (GAT1) functioning in 'reverse' to mediate release of GABA directly from the cytoplasm into the extracellular space. 25 Subcutaneous inoculation of the GAD-expressing vector into rodent footpad resulted in gene delivery to DRG neurons, transport of GAD protein to the afferent nerve terminals in the dorsal horn of spinal cord, and constitutive release of GABA into the dorsal horn. 24 In the selective L5 spinal nerve ligation model of neuropathic pain inoculation of the GAD-expressing vector produces an almost complete reversal of mechanical allodynia and a substantial reduction in thermal hyperalgesia 26 ( Figure 2 ). The time course of the GADmediated effect is slightly longer than that produced by either the enkephalin-or endomorphin-expressing HSV vectors. This time course likely reflects the underlying mechanisms of inhibitory neurotransmitter production from the respective vectors. In the case of the opioid peptides, once gene expression ceases the peptides are no longer expressed; in the case of the GABA vector, GAD protein produced from the vector will continue to generate GABA from glutamate for a time (related to the protein half-life) after gene expression is shutoff. The GAD-expressing vector also produced a statistically significant reduction in mechanical allodynia and thermal hyperalgesia in the spinal cord hemisection model of below-level pain after spinal cord injury. 24 Both the antiallodynic and anti-hyperalgesia effects of the vector were reversed in part by intrathecal administration of either the GABA A receptor antagonist, bicuculline, or the GABA B receptor antagonist, phaclofen, indicating that the effects of GABA released from the central terminals of the primary afferents are mediated in part by both GABA A and GABA B receptors. 24 Expression of inhibitory neurotransmitters represents an important avenue, by which nociceptive neurotransmission is interruped at the spinal level. An alternative approach involves the expression of peptides with antiinflammatory activity. An emerging body of evidence suggests that chronic pain is associated with activation of microglia and astrocytes within the dorsal horn of spinal cord, and that this neuroimmune activation plays an important role in the biology of the chronic pain state 27 and may interact in a direct manner with the therapeutic effect of opiate drugs. 28 Like inhibitory neurotransmitters though, the systemic administration of potent antiinflammatory peptides for the treatment of pain is likely to be problematic in a manner that could be overcome by the local delivery of these anti-inflammatory peptides to the dorsal horn of spinal cord. We have examined this possibility with a series of vectors expressing peptides with anti-inflammatory activity.
Subcutaneous inoculation of a non-replicating HSV vector engineered to express the interleukin-4 (IL-4) has no effect on tactile threshold or thermal latency in normal animals, but inoculation 1 week after selective L5 spinal nerve ligation reduces mechanical allodynia and reversed thermal hyperalgesia resulting from the nerve injury. 29 Vector-mediated IL-4 expression prevents the increase in IL-1b, PGE2 and phosphorylated p38 MAP kinase (pP38) in the dorsal horn of spinal cord that is characteristic of neuropathic pain in this model. 29 Inoculation of a nonreplicating HSV vector engineered to express IL-10 reduces pain-related behaviors in the formalin model of inflammatory pain concomitant with a reduction in pP38 and decreased expression of the fulllength membrane-spanning precursor of tumor necrosis factor a (mTNFa) in spinal microglia. 30 Direct interference with TNFa signaling by expression of a truncated form of the p55 TNFa receptor (p55 sTNFR) from a nonreplicating herpes vector inoculated into the skin results in a significant reduction in mechanical allodynia and thermal hyperalgesia in the selective L5 spinal nerve ligation model of neuropathic pain, concomitant with a reduction in pP38 and IL-1b in the dorsal horn, as well as a reduction in the expression of mTNFa in the spinal cord. 31 Similar results were observed in the T13 lateral hemisection model of below-level spinal cord injury pain in which subcutaneous inoculation of the p55 sTNFRexpressing vector attenuated mechanical allodynia, reduced phosphorylation of p38 and decreased expression of mTNFa in the dorsal horn. 32 In the immune system, mTNFa is capable of mediating bidirectional cell-cell interactions through binding directly to the membrane receptor complex (p55 or p75 TNFR) with both 'forward' signaling through the receptor complex and 'reverse' signaling in the ligand-expressing cell activated by the receptor. Downregulation of spinal mTNFa by vector-mediated expression of p55 sTNFR suggested that microglia mTNFa might play a similar reverse signaling role in the pathogenesis of neuropathic pain.
HSV vectors inoculated into the skin for the treatment of pain are likely to be safe. There is substantial clinical evidence from human studies involving injection of replication-competent oncolytic HSV delivered into tumors of brain (glioblastoma), breast, liver or skin in which the virus has been shown to be well tolerated and safe with no serious adverse events reported even with intracerebral inoculation. 33 These viruses did not reactivate endogenous HSV, 34, 35 did not cause encephalitis, 34, 36 nor spread appreciably from the site of inoculation. 34, 37 Generation of anti-HSV antibodies in patients is routinely reported but these responses are not robust. In addition, several clinical studies have been completed that used recombinant replication-competent HSV as a potential vaccine. The HSV-1 recombinant R7020 (now known as HSV-mediated gene transfer D Wolfe et al NV1020) was found safe and well tolerated in a phase 1 vaccine study, 38 and the HSV-2 based vector ICP10DPK was found safe and well tolerated in a phase 1/2 trial carried out in Mexico. 39 As no earlier studies have been performed using nonreplicating HSV vectors carrying therapeutic transgenes, we elected to move forward with a phase 1 trial in patients with pain from terminal cancer. We judged that this group of patients represents an appropriate population for a true phase 1 trial of this novel agent to establish the safety profile of the vector platform. Of the several different HSV-based vectors that we have tested in the osteolytic sarcoma model of pain from cancer, the analgesic effect of the enkephalinexpressing vector is as robust as that produced by any other vector and we proceeded to develop the enkephalin-expressing vector for the human trial.
The first HSV vectors to be used in models of pain were deleted for accessory viral functions (for example, thymidine kinase) that are important to virus replication in neurons and thus contribute to neurovirulence. Recombinant HSV defective in thymidine kinase can be propagated in culture and will replicate in skin, but are unable to replicate in the DRG and are thus forced into a pseudo-latent state. The vectors employed in our rodent studies were rendered replication defective by removal of essential virus genes (coding infected cell polypeptides (ICP) ICP4, ICP4 and ICP27 or ICP4, ICP27, ICP22 and ICP47). 2 These recombinants are propagated in cells that provide the missing gene product(s), in-trans.
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Although these vectors are completely incapable of replication in vivo, the recombinant particles retain the targeting properties of the wild-type virus and can be used to effectively deliver genes from the skin to the sensory ganglion where the vector establishes a persistent state in which no lytic viral genes are expressed.
To produce a vector appropriate for human use, the genomic HSV backbone and the complementing cell lines had to be reengineered. The critical deletions in the essential immediate early HSV genes, ICP4 and ICP27, in the vectors employed in the original preclinical animal studies do not delete the entire ICP4 or ICP27 open reading frames, but require a complementing cell line that contains the complete ICP4 and ICP27 coding regions to support the virus growth. The resultant residual homology between the vector and cell line leads to very low frequency rescue of the deletion(s) as the virus is propagated. To produce a high titer vector stock although eliminating the potential of homologous recombination producing replication competent recombinants that would be appropriate for human use the replication defective HSV backbone was reengineered to completely remove homology between the cell line and vector genomes (Figure 3) . The expanded ICP4 deletion in the clinically viable vector backbone also removes the upstream promoter elements of immediate early genes, ICP22 and ICP47 that restricts the expression of those genes to complementing cells. The complementing cell line was also reengineered by separately introducing the HSV genes, ICP4 and ICP27, stably into the genome of ATCC Vero cells. The clinical-grade replication defective ICP4 and ICP27 deleted HSV vector engineered to express human preproenkephalin was termed NP2.
Toxicology and biodistribution studies of the NP2 enkephalin-expressing vector were carried out according to Food and Drug Administration guidance. Four groups of 80 mice (40 male, 40 female) were dosed subcutaneously on study day 0. Group 1 received a single dose of phosphate buffered saline. Groups 2-4 were injected with NP2 at 1 Â 10 3 , 1 Â 10 5 and 1 Â 10 7 pfu per animal, respectively. Animals (10 mice per sex per group per time point) were killed on days 1, 7, 28 and 91 (1 day, 1 week, 1 month and 3 months) post-dosing. There was no evidence of adverse treatment-related effects of the test article as judged by clinical observations, body weight or food consumption. Clinical pathology showed no significant changes in hematology or clinical chemistry parameters at each time point. There were no treatmentrelated abnormalities in organ weights and macroscopic pathology. Histopathology examination showed no test article treatment-related microscopic changes. Incidentaland or spontaneous-histological changes were noted in, heart, sciatic nerve, spinal cord, injection site DRG and optic nerve in both control-and test article-treated groups; therefore, these findings were judged not to be test article-related. On the basis of predefined parameters of the toxicology study, administration of the test article according to the conditions of this study was well tolerated with no significant toxicity.
A total of 2400 tissues harvested from the in-life phase of the biodistribution study were examined for vector distribution. Using vector-specific primers a GLP qualified quantitative PCR assay was developed and DNAextraction efficiencies of target tissues performed. This assay has a limit of quantification of 20 copies and a limit of detection of between one and five copies. All tissues from the day 1 and day 7 cohorts were examined, as well as tissues from 10 animals of each sex from the control (phosphate buffered saline) group. In agreement with Food and Drug Administration guidance, because there was evidence of vector only at the injection site, innervating DRG, and underlying muscle in some day 1 and day 7 samples, only these tissues were analyzed in the day 28 and day 90 cohorts. A GAPDH normalization assay was included in separate reaction to calculate the total number of rat genomes present in the sample. All HSV and GAPDH target assays were run in duplicate. Each test included a negative control (no template) and positive control (target plasmid spike) to test for nontarget amplification and PCR inhibition, respectively. All samples were amplified using the Applied Biosystems Prism 7900 Sequence Detection System with standard cycling conditions for 45 cycles in a 50 ml reaction volume. No PCR inhibition was observed in any samples. No amplification was observed in negative control reactions. Control (phosphate buffered saline) injected animals did not show positive amplification in any case. A total of 1180 tissues were evaluated by having reached a stable maximum tolerable dose of narcotic or other analgesics that is less that 200 mg per day morphine or equivalent will be eligible to participate. The vector will be administered in 10 injections of 0.1 ml each within the dermatome(s) corresponding to the radicular distribution of the pain. Three-escalating dose levels with 3-6 patients at each dose level will be administered until (i) the maximum tolerated dose, defined as the highest dose with p1 of 6 patients having DLTs, or (ii) highest dose level is attained. The trial also contains an optional extension to recruit an additional of 12 patients to investigate efficacy potential. The primary outcome of this phase 1 safety/dose-finding trial will be adverse events, defined by history, physical examination and laboratory assessment. Efficacy will be assessed as a secondary outcome by a numeric-rating scale of pain intensity, the short form of the McGill Pain Questionnaire, performance status measured by the Eastern Cooperative Oncology Group Performance Status measure, a 12-item short-form health survey (SF-12) and the concurrent use of pain medications.
Based on the preclinical testing animal toxicology and biodistribution studies of NP2 and the extensive data from attenuated oncolytic herpes viruses that have been tested in patients we are relatively confident that NP2 will prove to be safe in the ongoing phase 1 study, but the design of this study with only three patients in each group and no placebo-control will make it difficult to realistically assess treatment efficacy. Efficacy will need to be tested in a subsequent phase 2 trial of inflammatory pain; chronic intractable focal pain from arthritis would appear to represent a reasonable target population for this study. Beyond inflammatory pain, chronic neuropathic pain represents a large unmet need for which there are few available effective therapies. In the case of painful diabetic neuropathy, for example, available medical treatments rarely reduce pain below a rating of four on a 0-10 analog pain scale, and only 30-40% of patients achieve a 50% reduction in pain beyond placebo effect. 41 As the GAD-expressing HSV vector is substantially more effective than the opioid peptide-(enkephalin or endomorphin) expressing vectors in the spinal nerve ligation model of neuropathic pain, we have engineered and begun testing of a clinicalgrade GAD-expressing HSV vector that, contingent on successful completion of the ongoing phase 1 study of NP2, could be tested in a phase 2 trial of patients with painful diabetic neuropathy. The outcome of these two phase 2 trials will represent an important decision point in the development of HSV vectors as a treatment for pain.
